Brooklyn ImmunoTherapeutics, Inc.
| We recently acquired a patented breakthrough mRNA technology platform, including mRNA-based cell reprogramming and gene editing technologies. Our platform includes novel LNPs for mRNA delivery and targeted transgene insertion. We are using these powerful tools to create next-generation mRNA, gene editing and cell therapies, including iPSC therapies for multiple therapeutic indications. |
